<DOC>
	<DOCNO>NCT01011530</DOCNO>
	<brief_summary>This open-label , multicenter , phase 1 , dose escalation study evaluate safety profile , establish Maximum Tolerated Dose ( MTD ) , inform recommend phase 2 dose MLN4924 well evaluate antitumor activity patient metastatic melanoma .</brief_summary>
	<brief_title>Dose Escalation Study MLN4924 Adults With Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<criteria>Each patient must meet follow criterion enrol study : Diagnosis metastatic melanoma Measurable disease Female patient post menopausal , surgically sterile , agree practice 2 effective method contraception abstain heterosexual intercourse Male patient agree practice effective barrier contraception agree abstain heterosexual intercourse Willing able give write informed consent Suitable venous access studyrequired blood sample Appropriate functional status , include recovery effect prior antineoplastic therapy , acceptable organ function describe protocol Patients meet follow exclusion criterion enrol study : Major surgery , serious infection , infection require systematic antibiotic therapy within 14 day first dose study drug Systemic antineoplastic radiation therapy within 14 day treatment investigational product within 21 day first dose study treatment CYP3A inducer within 14 day study treatment . Moderate strong CYP3A inhibitor CYP3A inducer permit study No prior history amiodarone 6 month first dose MLN4924 Diarrhea great Grade 1 outline protocol Evidence current uncontrolled cardiovascular condition , include cardiac arrhythmia , congestive heart failure , angina , myocardial infarction within past 6 month Known human immunodeficiency virus ( HIV ) positive , hepatitis B surface antigenpositive status , know suspect active hepatitis C infection . Serious medical psychiatric illness could , investigator 's opinion , potentially interfere completion treatment accord protocol Other clinical laboratory assessment meet criterion specify protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Melanoma</keyword>
</DOC>